<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526122</url>
  </required_header>
  <id_info>
    <org_study_id>G0041(75/100mg)_AS_Ⅰ</org_study_id>
    <nct_id>NCT01526122</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics &amp; Safety Study of Clopidogrel 75mg and Aspirin 100mg Coadministration</brief_title>
  <official_title>A PhaseⅠ Study to Compare the Pharmacokinetic Characteristics and Safety After Oral Administration of G0041(75/100mg) With Those of Clopidogrel 75mg &amp; Aspirin 100mg Coadministration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare characteristics and safety after oral administration
      of G0041(75/100mg) 2 tablets with those of Clopidogrel 75mg 2 tablets &amp; Aspirin 100mg 2
      capsules coadministration in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C(max) of Clopidogrel</measure>
    <time_frame>0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(last) of Clopidogrel</measure>
    <time_frame>0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C(max) of Acetylsalicylic acid</measure>
    <time_frame>0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(last) of Acetylsalicylic acid</measure>
    <time_frame>0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C(max) of Salicylic acid</measure>
    <time_frame>0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(last) of Salicylic acid</measure>
    <time_frame>0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>G0041(75/100mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel &amp; Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G0041(75/100mg)</intervention_name>
    <description>G0041(75/100mg) 2 capsules(Clopidogrel 75mg &amp; Aspirin 100mg in 1 capsule), PO</description>
    <arm_group_label>G0041(75/100mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel &amp; Aspirin</intervention_name>
    <description>Clopidogrel 75mg 2 tablets &amp; Aspirin 100mg 2 capsules, PO</description>
    <arm_group_label>Clopidogrel &amp; Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male volunteers between the ages of 20 to 50 years old

          -  weight more than 55kg and within the range of ±20% of IBW

          -  having neither congenital/chronic diseases nor pathological symptoms/findings as
             results of medical examination

          -  doctor determines to be suitable as subjects within 3 weeks ago before administration

        Exclusion Criteria:

          -  Hypersensitivitiy(or history of hypersensitivity) to aspirin and clopidogrel

          -  Active Liver Diseases or exceed 1.5 times the normal range of AST, ALT, total
             bilirubin

          -  Exceed the normal range of PT, aPTT, BT &amp; platelet counts under 150,000/㎣ or exceed
             350,000/㎣

          -  Creatinine clearance &lt; 80 mL/min

          -  Gastrointestinal diseases or surgeries that affect absorption of drug

          -  Congenital galactose intolerance, lactase deficiency and glucose-galactose
             malabsorption

          -  Excessive drinking(exceed 21units/week)

          -  Smoking over 10 cigarettes per day
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-ran Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <reference>
    <citation>Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010 Jan;32(1):161-70. doi: 10.1016/j.clinthera.2010.01.010.</citation>
    <PMID>20171421</PMID>
  </reference>
  <reference>
    <citation>Bae SK, Seo KA, Jung EJ, Kim HS, Yeo CW, Shon JH, Park KM, Liu KH, Shin JG. Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed Chromatogr. 2008 Jun;22(6):590-5. doi: 10.1002/bmc.973.</citation>
    <PMID>18254152</PMID>
  </reference>
  <reference>
    <citation>Kim SD, Kang W, Lee HW, Park DJ, Ahn JH, Kim MJ, Kim EY, Kim SW, Nam HS, Na HJ, Yoon YR. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther. 2009 Apr;31(4):793-803. doi: 10.1016/j.clinthera.2009.04.017.</citation>
    <PMID>19446152</PMID>
  </reference>
  <reference>
    <citation>EMEA(2009), CHMP assessment report of DuoCover. EMEA/H/C/001144</citation>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Aspirin</keyword>
  <keyword>coadministration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

